Investigation of Prognostic Factors of Survival in Breast Cancer Using a Frailty Model: A Multicenter Study.
breast cancer
frailty model
prognostic factor
survival
Journal
Breast cancer : basic and clinical research
ISSN: 1178-2234
Titre abrégé: Breast Cancer (Auckl)
Pays: United States
ID NLM: 101474356
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
09
2019
accepted:
05
09
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
Using data from different health centers can provide more accurate knowledge of the survival prognostic factors and their effect on the patient's survival. In this multicenter study, we aimed to investigate the role of prognostic factors on breast cancer survival with large data set. This historical cohort study was carried out using data from 1785 participants with breast cancer. Data were gathered from medical records of patients referring to 4 breast cancer research centers in Tehran, Iran, between 1997 and 2013. Age at diagnosis (year), size of the tumor, involve lymph nodes, tumor grade, type of surgery, auxiliary treatment of chemotherapy, radiotherapy, recurrence, and metastasis were the prognosis factors considered in this study. A shared frailty model with a gamma distribution for frailty term was used. The median follow-up period was 29.71 months with the interquartile range of 19 to 61 months. During the follow-up period, 337 (18.9%) patients died from breast cancer and 1448 (81.1%) survived. The 1-, 3-, 5-, and 10-year survival rates were 96%, 84%, 76%, and 58%, respectively. In the Cox model by centers, in Center A, the type of surgery, number of nodes involved, and the grade 3 tumor; in center B, age, radiotherapy, metastasis, and between 1 and 3 involved nodes; in center C, age, radiotherapy, recurrence, metastasis, tumor size, and grade 3 tumor; and in center D, chemotherapy, metastasis, and lymph nodes involved were significant. Shared frailty model showed that type of surgery, number of lymph nodes involved, metastasis, radiotherapy, and the tumor grade are the prognostic factors survival in breast cancer. The frailty variance was significant, and it affirmed there was significant variability between centers. This study showed it is necessary to consider the frailty term in modeling multicenter survival studies and confirmed the importance of early diagnosis of cancer before the involvement of lymph nodes and the onset of metastasis and timely treatment could lead to longer life and increased quality of life for patients.
Sections du résumé
BACKGROUND
BACKGROUND
Using data from different health centers can provide more accurate knowledge of the survival prognostic factors and their effect on the patient's survival. In this multicenter study, we aimed to investigate the role of prognostic factors on breast cancer survival with large data set.
METHODS
METHODS
This historical cohort study was carried out using data from 1785 participants with breast cancer. Data were gathered from medical records of patients referring to 4 breast cancer research centers in Tehran, Iran, between 1997 and 2013. Age at diagnosis (year), size of the tumor, involve lymph nodes, tumor grade, type of surgery, auxiliary treatment of chemotherapy, radiotherapy, recurrence, and metastasis were the prognosis factors considered in this study. A shared frailty model with a gamma distribution for frailty term was used.
RESULTS
RESULTS
The median follow-up period was 29.71 months with the interquartile range of 19 to 61 months. During the follow-up period, 337 (18.9%) patients died from breast cancer and 1448 (81.1%) survived. The 1-, 3-, 5-, and 10-year survival rates were 96%, 84%, 76%, and 58%, respectively. In the Cox model by centers, in Center A, the type of surgery, number of nodes involved, and the grade 3 tumor; in center B, age, radiotherapy, metastasis, and between 1 and 3 involved nodes; in center C, age, radiotherapy, recurrence, metastasis, tumor size, and grade 3 tumor; and in center D, chemotherapy, metastasis, and lymph nodes involved were significant. Shared frailty model showed that type of surgery, number of lymph nodes involved, metastasis, radiotherapy, and the tumor grade are the prognostic factors survival in breast cancer. The frailty variance was significant, and it affirmed there was significant variability between centers.
CONCLUSIONS
CONCLUSIONS
This study showed it is necessary to consider the frailty term in modeling multicenter survival studies and confirmed the importance of early diagnosis of cancer before the involvement of lymph nodes and the onset of metastasis and timely treatment could lead to longer life and increased quality of life for patients.
Identifiants
pubmed: 31632048
doi: 10.1177/1178223419879112
pii: 10.1177_1178223419879112
pmc: PMC6769229
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178223419879112Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cancer. 2001 Apr 15;91(8 Suppl):1679-87
pubmed: 11309768
J Res Health Sci. 2012 Dec 13;12(2):127-30
pubmed: 23241526
Arch Iran Med. 2010 Mar;13(2):143-6
pubmed: 20187669
Arch Gerontol Geriatr. 2018 May - Jun;76:60-64
pubmed: 29459246
Asian Pac J Cancer Prev. 2015;16(18):8567-71
pubmed: 26745118
Medicine (Baltimore). 2017 Jan;96(4):e5998
pubmed: 28121956
Ann Surg Oncol. 2015 Nov;22(12):3836-45
pubmed: 25743325
East Mediterr Health J. 2018 Jan 2;23(11):721-728
pubmed: 29319143
Lancet Oncol. 2008 Aug;9(8):730-56
pubmed: 18639491
Hum Pathol. 2017 Jun;64:53-60
pubmed: 28428107
Lancet Oncol. 2012 Apr;13(4):412-9
pubmed: 22373563
World J Surg Oncol. 2017 Jul 3;15(1):118
pubmed: 28673296
Lifetime Data Anal. 1995;1(3):255-73
pubmed: 9385105
J Surg Oncol. 2017 Feb;115(2):122-130
pubmed: 28054348
BMC Cancer. 2009 Jun 05;9:168
pubmed: 19497131
Breast Cancer Res Treat. 2008 Feb;107(3):309-30
pubmed: 17377838
Cancer. 2004 Jan 1;100(1):44-52
pubmed: 14692023
Eat Weight Disord. 2018 Jun 22;:null
pubmed: 29931448
Asian Pac J Cancer Prev. 2004 Apr-Jun;5(2):223-5
pubmed: 15244529
Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):275-8
pubmed: 18712973
Stat Med. 2002 Aug 30;21(16):2345-54
pubmed: 12210619
Public Health. 2015 May;129(5):549-54
pubmed: 25753278
Eur J Surg Oncol. 2015 Oct;41(10):1417-22
pubmed: 26253193
Clin Breast Cancer. 2016 Dec;16(6):500-506.e2
pubmed: 27431462
J Clin Oncol. 2000 Mar;18(6):1220-9
pubmed: 10715291
Breast J. 2018 Nov;24(6):1129-1131
pubmed: 30240101
Biometrics. 2004 Sep;60(3):608-14
pubmed: 15339282
J Cancer Res Ther. 2016 Jul-Sep;12(3):1184-1188
pubmed: 28054533
BMC Gastroenterol. 2011 Oct 01;11:104
pubmed: 21961837
Iran Red Crescent Med J. 2012 Dec;14(12):798-804
pubmed: 23483369
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Clin Breast Cancer. 2016 Aug;16(4):e113-8
pubmed: 27036361
Breast Cancer (Auckl). 2019 Feb 22;13:1178223419830978
pubmed: 30828246
Asian Pac J Cancer Prev. ;17(10):4615-4621
pubmed: 27892673